What's Happening?
Researchers at Memorial Sloan Kettering (MSK) Cancer Center have made significant advancements in CAR T-cell therapy, traditionally used for blood cancers, by targeting solid tumors. The new approach focuses on the urokinase plasminogen activator receptor
(uPAR), a surface protein found in the tumor microenvironment. This method addresses the challenge of solid tumors, which often lack a consistent surface target and are protected by scar tissue and immune-suppressive cells. The study, published in Cell, reveals that uPAR is elevated in 12 of 14 human cancer types analyzed, particularly in those with mutations affecting the p53 tumor-suppressor gene and the RAS pathway. The engineered CAR T-cells have shown effectiveness in shrinking various solid tumors, including lung, pancreatic, and ovarian cancers, and even clearing metastases in preclinical models.
Why It's Important?
This development is crucial as it represents a potential breakthrough in treating solid tumors, which have been resistant to traditional CAR T-cell therapies. By targeting uPAR, the therapy can attack not just the tumor cells but also the supportive cells that create a protective environment for tumor growth. This could lead to more effective treatments for aggressive cancers, offering hope for patients with limited options. The ability to target cells in a specific state rather than a type could revolutionize cancer treatment, making it more adaptable and potentially more successful in eradicating tumors.
What's Next?
The research team plans to further explore the use of uPAR-targeted CAR T-cells in combination with other treatments, such as chemotherapy agents like cisplatin, to enhance therapeutic effects. Additionally, they are investigating non-invasive methods to monitor uPAR-high disease, such as blood tests for suPAR and uPAR-targeted PET scans. These advancements could lead to more personalized and precise cancer treatments, improving patient outcomes and potentially leading to clinical trials in humans.
Beyond the Headlines
The implications of this research extend beyond CAR T-cell therapy. uPAR can also be targeted using other methods, such as antibody-drug conjugates and CAR-based natural killer cell treatments. This versatility highlights the potential for uPAR-targeted therapies to become a cornerstone in cancer treatment, offering new avenues for tackling resistant solid tumors. The study underscores the importance of understanding the tumor microenvironment and its role in cancer progression, which could lead to broader applications in oncology.
